Catherine Daniel

Summary

Affiliation: Institut de Biologie de Lille
Country: France

Publications

  1. pmc Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model
    Catherine Daniel
    Laboratoire des Bactéries Lactiques et Immunité des Muqueuses, Institut Pasteur de Lille, 59019 Lille Cedex, France
    Appl Environ Microbiol 72:5799-805. 2006
  2. pmc Bioluminescence imaging study of spatial and temporal persistence of Lactobacillus plantarum and Lactococcus lactis in living mice
    Catherine Daniel
    Institut Pasteur de Lille, Lactic acid Bacteria and Mucosal Immunity, Center for Infection and Immunity of Lille, Lille, France
    Appl Environ Microbiol 79:1086-94. 2013
  3. doi request reprint Recombinant lactic acid bacteria as mucosal biotherapeutic agents
    Catherine Daniel
    Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Universite Lille Nord de France, CNRS, UMR 8204, Institut National de la Sante et de la Recherche Medicale, U1019, F 59019 Lille, France
    Trends Biotechnol 29:499-508. 2011
  4. doi request reprint Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV
    Catherine Daniel
    Laboratoire des Bactéries Lactiques et Immunité des Muqueuses, Institut Fédératif de Recherche 142, Institut Pasteur de Lille, Lille F 59021, France
    Vaccine 27:1141-4. 2009
  5. ncbi request reprint Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein
    Benoit Foligne
    Laboratoire des Bactéries Lactiques et Immunité des Muqueuses, Institut Pasteur de Lille, Lille, France
    Gastroenterology 133:862-74. 2007
  6. ncbi request reprint Therapeutic potential of Yersinia anti-inflammatory components
    Benoit Foligne
    Inserm U801, Faculté de Médecine Institut Pasteur de Lille, Universite de Lille, France
    Adv Exp Med Biol 603:361-6. 2007
  7. doi request reprint Gut microbiota limits heavy metals burden caused by chronic oral exposure
    Jerome Breton
    Bactéries Lactiques and Immunité des Muqueuses, Centre d Infection et d Immunité de Lille, Institut Pasteur de Lille, INSERM U 1019, CNRS UMR 8204 Université Lille Nord de France, 1 rue du Pr Calmette, BP 245, F 59019 Lille, France
    Toxicol Lett 222:132-8. 2013
  8. doi request reprint Probiotics from research to market: the possibilities, risks and challenges
    Benoit Foligne
    Institut Pasteur de Lille, Lactic acid Bacteria and Mucosal Immunity, Center for Infection and Immunity of Lille, 1, rue du Pr Calmette, BP 245, F 59019 Lille, France Univ Lille Nord de France, F 59000 Lille, France CNRS, UMR 8204, F 59021 Lille, France Institut National de la Santé et de la Recherche Médicale, U1019, F 59019 Lille, France
    Curr Opin Microbiol 16:284-92. 2013
  9. ncbi request reprint Potential and opportunities for use of recombinant lactic acid bacteria in human health
    Sean Hanniffy
    Institute of Food Research, Norwich Research Park, Colney, Norwich, NR4 7UA, United Kingdom
    Adv Appl Microbiol 56:1-64. 2004
  10. ncbi request reprint Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy
    Andreas Repa
    Department of Pathophysiology, Medical School AKH EBO3Q, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Vaccine 22:87-95. 2003

Collaborators

  • Michiel Kleerebezem
  • Michael Marceau
  • Florent Sebbane
  • Corinne Grangette
  • Jean Fioramonti
  • P Hols
  • Benoit Foligne
  • Jerome Breton
  • Andreas Repa
  • Nathalie Guriec
  • Sean Hanniffy
  • Annick Mercenier
  • Ursula Wiedermann
  • Bruno Pot
  • Stéphanie Pothion
  • Nathalie Froux
  • Joelle Dewulf
  • Patrick Thomas
  • Mathieu Sauty
  • Elisabeth Hardy
  • Karine Le Ster
  • Christian Berthou
  • Søren Madsen
  • Hans Israelsen
  • Peter Bron
  • Astrid Vrang
  • Hana Kozakova
  • Jerry Wells
  • Jean Delcour
  • Helena Tlaskolova
  • Romana Hochreiter
  • Heimo Breiteneder
  • Dietrich Kraft
  • Karin Hoffmann-Sommergruber
  • Josef Thalhamer

Detail Information

Publications12

  1. pmc Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model
    Catherine Daniel
    Laboratoire des Bactéries Lactiques et Immunité des Muqueuses, Institut Pasteur de Lille, 59019 Lille Cedex, France
    Appl Environ Microbiol 72:5799-805. 2006
    ..We conclude that not all lactobacilli have similar effects on intestinal inflammation and that selected probiotics such as L. salivarius Ls-33 may be considered in the prevention or treatment of intestinal inflammation...
  2. pmc Bioluminescence imaging study of spatial and temporal persistence of Lactobacillus plantarum and Lactococcus lactis in living mice
    Catherine Daniel
    Institut Pasteur de Lille, Lactic acid Bacteria and Mucosal Immunity, Center for Infection and Immunity of Lille, Lille, France
    Appl Environ Microbiol 79:1086-94. 2013
    ..The application of luciferase-labeled bacteria has significant potential to allow the in vivo and ex vivo study of the interactions of lactic acid bacteria with their mammalian host...
  3. doi request reprint Recombinant lactic acid bacteria as mucosal biotherapeutic agents
    Catherine Daniel
    Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Universite Lille Nord de France, CNRS, UMR 8204, Institut National de la Sante et de la Recherche Medicale, U1019, F 59019 Lille, France
    Trends Biotechnol 29:499-508. 2011
    ..In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health...
  4. doi request reprint Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV
    Catherine Daniel
    Laboratoire des Bactéries Lactiques et Immunité des Muqueuses, Institut Fédératif de Recherche 142, Institut Pasteur de Lille, Lille F 59021, France
    Vaccine 27:1141-4. 2009
    ..pseudotuberculosis infections. This constitutes the first proof of principle for a novel anti-Yersinia mucosal vaccination strategy using recombinant lactic acid bacteria...
  5. ncbi request reprint Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein
    Benoit Foligne
    Laboratoire des Bactéries Lactiques et Immunité des Muqueuses, Institut Pasteur de Lille, Lille, France
    Gastroenterology 133:862-74. 2007
    ....
  6. ncbi request reprint Therapeutic potential of Yersinia anti-inflammatory components
    Benoit Foligne
    Inserm U801, Faculté de Médecine Institut Pasteur de Lille, Universite de Lille, France
    Adv Exp Med Biol 603:361-6. 2007
    ..This is the case for virulence plasmid-encoded proteins from pathogenic Yersiniae that inhibit the host's inflammatory response by interfering with various cellular signaling pathways...
  7. doi request reprint Gut microbiota limits heavy metals burden caused by chronic oral exposure
    Jerome Breton
    Bactéries Lactiques and Immunité des Muqueuses, Centre d Infection et d Immunité de Lille, Institut Pasteur de Lille, INSERM U 1019, CNRS UMR 8204 Université Lille Nord de France, 1 rue du Pr Calmette, BP 245, F 59019 Lille, France
    Toxicol Lett 222:132-8. 2013
    ..Collectively, these data illustrate the complex host-microbes interplay occurring with environmental pollutants inside the gut. ..
  8. doi request reprint Probiotics from research to market: the possibilities, risks and challenges
    Benoit Foligne
    Institut Pasteur de Lille, Lactic acid Bacteria and Mucosal Immunity, Center for Infection and Immunity of Lille, 1, rue du Pr Calmette, BP 245, F 59019 Lille, France Univ Lille Nord de France, F 59000 Lille, France CNRS, UMR 8204, F 59021 Lille, France Institut National de la Santé et de la Recherche Médicale, U1019, F 59019 Lille, France
    Curr Opin Microbiol 16:284-92. 2013
    ..This review discusses the crosstalk between probiotic producers, regulatory people, medical care and healthcare workers, and the scientific community. ..
  9. ncbi request reprint Potential and opportunities for use of recombinant lactic acid bacteria in human health
    Sean Hanniffy
    Institute of Food Research, Norwich Research Park, Colney, Norwich, NR4 7UA, United Kingdom
    Adv Appl Microbiol 56:1-64. 2004
  10. ncbi request reprint Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy
    Andreas Repa
    Department of Pathophysiology, Medical School AKH EBO3Q, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Vaccine 22:87-95. 2003
    ..We conclude that these LAB strains in combination with an allergen could be promising candidates for mucosal vaccination against type I allergy...
  11. ncbi request reprint Use of a pleural implantable access system for the management of malignant pleural effusion: the Institut Curie experience
    Catherine Daniel
    Institut Curie, Paris, France
    Ann Thorac Surg 84:1367-70. 2007
    ..The authors report the first experience of a pleural implantable access system for the treatment of recurrent symptomatic malignant pleural effusion...
  12. ncbi request reprint Cytokine-regulated expression and inhibitory function of FcgammaRIIB1 and -B2 receptors in human dendritic cells
    Nathalie Guriec
    Cellular Therapy Laboratory, Brest Medical School, France
    J Leukoc Biol 79:59-70. 2006
    ..Altogether, our results evidence an inhibitory role for FcgammaRIIB in human DC and provide an easy way to possibly improve in vitro the induction of immune response against IC-linked antigen...